FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2763452826> ?p ?o ?g. }

• W2763452826 endingPage "9" @default.
• W2763452826 startingPage "1" @default.
• W2763452826 abstract "The seventh Edition of Innovative Therapy, Monoclonal Antibodies and Beyond Meeting took place in Milan, Italy, on January 27, 2017. The two sessions of the meeting were focused on: 1) Preclinical assays and novel biotargets; and 2) monoclonal antibodies, cell therapies and targeted molecules. Between these two sessions, a lecture entitled HLA-antigens modulation and response to immune checkpoint inhibitor immunotherapy was also presented. Despite the impressive successes in cancer immunotherapy in recent years, the response to immune based interventions occurs only in a minority of patients (∼20%). Several basic and translational mechanisms of resistance to immune checkpoint blockers (ICBs) were discussed during the meeting: 1. the impact of tumor microenvironment on the activity of immune system; 2. strategies to inhibit the cross-talk between extracellular matrix and myeloid-derived suppressor cells (MDSC) in the preclinical setting; 3. microRNA expression as a biomarker and as a target of therapy in non-small cell lung cancer (NSCLC); 4. the significance of complement activation pathways in response to immune checkpoint inhibitors; 5. the immunosuppressive activity of the microbiota by inducing IL-17 producing cells; and 6. modulation of HLA antigens as possible markers of response to ICB therapy. In order to overcome the deficiency in active anti-tumor T cells, several clinically applicable combination strategies were also discussed: 1. strategies to enhance the anticancer effects of immunogenic cell death inducing-chemotherapy; 2. the use of CAR T-cells in solid tumors; 3. the use of combination strategies involving oncolytic viruses and ICBs; 4. combinations of new ICBs with anti-PD-1/CTLA-4 therapy; and 4. combinations of targeted therapies and ICBs in melanoma. Overall, this conference emphasized the many novel strategies that are being investigated to improve the overall patient response to cancer immunotherapy. Optimization of biomarkers to accurately select patients who will respond to immunotherapy, coupled with combination strategies to improve long term patient survival remain critical challenges in the immuno-oncology field." @default.
• W2763452826 created "2017-10-20" @default.
• W2763452826 creator A5000391768 @default.
• W2763452826 creator A5001956192 @default.
• W2763452826 creator A5017539817 @default.
• W2763452826 creator A5020944852 @default.
• W2763452826 creator A5023649972 @default.
• W2763452826 creator A5042737704 @default.
• W2763452826 creator A5044426445 @default.
• W2763452826 creator A5052353123 @default.
• W2763452826 creator A5066576514 @default.
• W2763452826 creator A5077760288 @default.
• W2763452826 creator A5081264460 @default.
• W2763452826 creator A5088229816 @default.
• W2763452826 date "2017-12-01" @default.
• W2763452826 modified "2023-10-18" @default.
• W2763452826 title "Innovative Therapy, Monoclonal Antibodies and Beyond" @default.
• W2763452826 cites W1533959918 @default.
• W2763452826 cites W1964309870 @default.
• W2763452826 cites W1977949161 @default.
• W2763452826 cites W1992407986 @default.
• W2763452826 cites W1992750664 @default.
• W2763452826 cites W1993515057 @default.
• W2763452826 cites W1996479902 @default.
• W2763452826 cites W2009959651 @default.
• W2763452826 cites W2011513757 @default.
• W2763452826 cites W2012182672 @default.
• W2763452826 cites W2016612145 @default.
• W2763452826 cites W2023594496 @default.
• W2763452826 cites W2027863358 @default.
• W2763452826 cites W2031110738 @default.
• W2763452826 cites W2039687494 @default.
• W2763452826 cites W2039888051 @default.
• W2763452826 cites W2040956995 @default.
• W2763452826 cites W2052034341 @default.
• W2763452826 cites W2053146807 @default.
• W2763452826 cites W2056320810 @default.
• W2763452826 cites W2066671159 @default.
• W2763452826 cites W2068537935 @default.
• W2763452826 cites W2071255079 @default.
• W2763452826 cites W2073924079 @default.
• W2763452826 cites W2074390009 @default.
• W2763452826 cites W2077553363 @default.
• W2763452826 cites W2080926419 @default.
• W2763452826 cites W2081614156 @default.
• W2763452826 cites W2084510390 @default.
• W2763452826 cites W2085153086 @default.
• W2763452826 cites W2087055812 @default.
• W2763452826 cites W2087484128 @default.
• W2763452826 cites W2092902493 @default.
• W2763452826 cites W2093424661 @default.
• W2763452826 cites W2094481139 @default.
• W2763452826 cites W2094945699 @default.
• W2763452826 cites W2114903025 @default.
• W2763452826 cites W2115848444 @default.
• W2763452826 cites W2115983165 @default.
• W2763452826 cites W2118796952 @default.
• W2763452826 cites W2120126501 @default.
• W2763452826 cites W2125455308 @default.
• W2763452826 cites W2126758513 @default.
• W2763452826 cites W2130153302 @default.
• W2763452826 cites W2132406938 @default.
• W2763452826 cites W2136100686 @default.
• W2763452826 cites W2138977450 @default.
• W2763452826 cites W2142160537 @default.
• W2763452826 cites W2143550961 @default.
• W2763452826 cites W2164918734 @default.
• W2763452826 cites W2166662937 @default.
• W2763452826 cites W2182836097 @default.
• W2763452826 cites W2204750960 @default.
• W2763452826 cites W2207230085 @default.
• W2763452826 cites W2208752319 @default.
• W2763452826 cites W2233291722 @default.
• W2763452826 cites W2254642444 @default.
• W2763452826 cites W2262128896 @default.
• W2763452826 cites W2418354692 @default.
• W2763452826 cites W2465860350 @default.
• W2763452826 cites W2466689966 @default.
• W2763452826 cites W2473498748 @default.
• W2763452826 cites W2508710837 @default.
• W2763452826 cites W2534772180 @default.
• W2763452826 cites W2587048937 @default.
• W2763452826 cites W2604405073 @default.
• W2763452826 cites W2610264191 @default.
• W2763452826 cites W2616637874 @default.
• W2763452826 cites W2622499649 @default.
• W2763452826 cites W2744517306 @default.
• W2763452826 cites W2748217844 @default.
• W2763452826 cites W4211238487 @default.
• W2763452826 doi "https://doi.org/10.1016/j.cytogfr.2017.10.002" @default.
• W2763452826 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29029813" @default.
• W2763452826 hasPublicationYear "2017" @default.
• W2763452826 type Work @default.
• W2763452826 sameAs 2763452826 @default.
• W2763452826 citedByCount "5" @default.
• W2763452826 countsByYear W27634528262018 @default.
• W2763452826 countsByYear W27634528262022 @default.
• W2763452826 crossrefType "journal-article" @default.

• next